Ipsen and Skyhawk Therapeutics signed worldwide collaboration to discover and develop RNA targeting small molecules for rare neurological diseases
Under the collaboration, Ipsen has option to acquire exclusive global rights to develop and commercialize two molecules, post successful development candidate validation
As per the terms of agreement, Skyhawk will receive ~$1.8B in upfront, development, regulatory & commercial milestones, plus tiered royalties
Ref: Ipsen | Image: Ipsen
Related News:- Ipsen and Sutro Biopharma Collaborate to Develop and Commercialize STRO-003 for Treating Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
